Pharming Group (PHARM) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenues rose 12% year-over-year to $74.8M, driven by strong RUCONEST and Joenja growth, with nine-month revenues up 25% to $204.5M.

• RUCONEST remains a key revenue generator with strong U.S. demand and increased enrollments; Joenja commercialization expanded in the U.S., U.K., and Israel.

• Joenja nine-month revenue reached $31.9M, up 210% year-over-year, with global expansion and new approvals.

• CEO Sijmen de Vries to step down after 16 years, with a succession process underway.

• Cash and marketable securities stood at $173.3M at Q3 end, providing a solid liquidity position.

Financial highlights

• Q3 2024 revenues: $74.8M (+12% YoY); nine-month revenues: $204.5M (+25% YoY).

• Q3 2024 gross profit: $68.0M (91% margin); operating profit: $4.1M (5.5% margin); net loss: $1.0M due to higher finance expenses.

• Nine-month 2024 net loss: $14.7M; operating loss: $15.3M (improved from $17.1M loss last year, excluding one-offs).

• Cash and marketable securities at $173.3M at Q3 end, down from $215.0M at 2023 year-end due to bond refinancing.

• Q3 2024 cash flow from operations was $9.7M, up from $3.5M in Q3 2023.

Outlook and guidance

• 2024 total revenue guidance reaffirmed at $280M–$295M, representing 14–20% growth.

• Continued growth expected for RUCONEST and Joenja, with high patient adherence and stable U.S. pricing.

• Growth drivers include new indications, pediatric label expansion, and launches in Japan, EU, Canada, and Australia.

• Advancing Phase II trial for leniolisib in PIDs and ongoing business development for rare disease assets.

• OpEx expected to remain stable in Q4; cost base will be adjusted if Joenja growth slows, aiming for profitability.